Aroop Mangalik, MD; James Neidhart, MD
To the Editors: Levine and colleagues (1), presented a useful tool for eliciting patient preference for adjuvant chemotherapy that gives a statistical perspective on the risks and benefits. However, they did not discuss another major and important method of dealing with the uncertainty of the situation in node-negative breast cancer: participation in randomized clinical trials. Not enough patients are being enrolled in clinical trials, making it difficult to answer important clinical questions such as those concerning risks and benefits in different sub-populations (2, 3).
By participating in a clinical trial, the patient gets information about the current state of knowledge
Mangalik A, Neidhart J. Randomized Clinical Trials and Patient Preferences. Ann Intern Med. ;117:700. doi: 10.7326/0003-4819-117-8-700_1
Download citation file:
Published: Ann Intern Med. 1992;117(8):700.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use